Apellis Pharmaceuticals (APLS) Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Apellis Pharmaceuticals, Inc., (Nasdaq:NASDAQ:), a global biopharmaceutical company and leading supplement, announced today that it has commenced a $300 million underwritten public offering of its common shares (or pre-funded warrants to purchase its common shares in lieu of ). Apellis offers all common shares and warrants pre-funded. In addition, Apellis expects to grant underwriters a 30-day option to purchase additional shares of its capital stock for an amount equal to 15% of the securities offered in the public offering.
JP Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group LLC are acting as joint book managers for the offering. Robert W. Baird & Co. Incorporated and Raymond James & Associates, Inc. are serving as co-managers of the offering. The proposed offer is subject to market and other conditions, and there can be no guarantee if or when the offer will be completed, or the actual size or terms of the offer.
The securities are being offered by Apellis pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission (“SEC”) on February 22, 2023.
This offer is made solely by way of a prospectus and prospectus supplement which form part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering describing the terms of the offering are expected to be filed with the SEC and, if and when filed, copies of the preliminary prospectus supplement relating to the offering may be obtained. the offer for free by visiting the SEC’s website. website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus may also be obtained by contacting: JP Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by phone at 866-803-9204, or by email to prospectus-eq_fi@jpmchase.com; Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, NY 10282, or by phone at (866) 471-2526, or by email at prospect-ny@ny.email.gs.com; o Evercore Group LLC, Attn: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by phone at (888) 474-0200, or by email at ecm.prospectus@evercore.com. The final terms of the offering will be disclosed in a supplement to the final prospectus to be filed with the SEC.